We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Abbott Diagnostics

Download Mobile App


ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.

Transformational Stent Uncages the Unyielding Artery

By HospiMedica International staff writers
Posted on 22 Nov 2017
Print article
Image: A novel dynamic drug eluting stent allows arteries to pulsate (Photo courtesy of Elixir Medical).
Image: A novel dynamic drug eluting stent allows arteries to pulsate (Photo courtesy of Elixir Medical).
A novel bioadaptive drug eluting stent (DES) becomes more flexible over time, allowing pulsatile motion to take over the vessel.

The Elixir Medical (Sunnyvale, CA, USA) DynamX cobalt chromium stent is a 71 microns thin cobalt-chromium DES with a thin, biodegradable polymer coating that releases Novolimus, an anti-proliferative and anti-inflammatory drug. The stent is composed of adaptive segments that are held intact by the biodegradable polymer coating, designed to absorb within six months, thus allowing the adaptive segments to uncage the stent and subsequently restore the natural pulsatile motion and adaptive remodeling of the artery.

This allows the vessel to resume arterial pulsatile motion and the Glagovian phenomenon of adaptive remodeling, which are both essential for slowing disease progression and minimizing clinical events. In clinical studies, the DynamX demonstrated significantly improved conformability and reduced torsional and longitudinal stresses compared to current drug eluting stents, thereby reducing geometric distortion of arteries and the potential for stent fractures or other clinical events.

“Elixir is committed to lead the industry to a new and exciting era with its bio-adaptive DynamX drug eluting stent,” said Motasim Sirhan, CEO of Elixir Medical. “Elixir is executing on a two-pronged strategy with bioresorbable and bioadaptive drug eluting stent to develop innovative, adaptive remodeling technologies designed to restore the normal function of arteries.”

Novolimus is an active metabolite of Sirolimus with anti-proliferative and anti-inflammatory properties. Sirolimus, in its turn, is the most widely known mammalian target of rapamycin (mTOR) macrocyclic lactone inhibitor, used in various treatment applications such as drug eluting stents, transplant, and oncology.

Related Links:
Elixir Medical

Print article


Copyright © 2000-2020 Globetech Media. All rights reserved.